DrugCentral: online drug compendium
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
DrugCentral (http://drugcentral.org) is an open-access online drug compendium. DrugCentral integrates structure, bioactivity, regulatory, pharmacologic actions and indications for active pharmaceutical ingredients approved by FDA and other regulatory agencies. Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date. DrugCentral integrates content for active ingredients with pharmaceutical formulations, indexing drugs and drug label annotations, complementing similar resources available online. Its complementarity with other online resources is facilitated by cross referencing to external resources. At the molecular level, DrugCentral bridges drug-target interactions with pharmacological action and indications. The integration with FDA drug labels enables text mining applications for drug adverse events and clinical trial information. Chemical structure overlap between DrugCentral and five online drug resources, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chemical collections, are discussed. DrugCentral can be accessed via the web application or downloaded in relational database format.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are 217 drugs annotated in DrugCentral10 as acting through 125 (T) ion channels for the MoA9.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chemical structures were manually assigned to 140 of the latest veterinary drugs, and molecular descriptors and structure depictions were computed per DrugCentral workflow (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“DrugCentral has been a public digital database aggregating drug information since 2016 (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
KEGG for integration and interpretation of large-scale molecular data sets
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., & Tanabe, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr988 · Cited by 4,848 · cited 2×
“The following resources matched our above inclusion criteria: the ChEMBL database (1), the Guide to Pharmacology (2) and KEGG Drug (3).”
BackgroundMethodThe unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427 · cited 1×
“) to which the API or its active metabolite binds directly, to exert the therapeutic drug action (22).”
BackgroundSelf-citationDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 10×
“The overlap matrix was computed for DrugCentral, in comparison with the following drugfocused resources: the NIH Center for Chemical Genomics (NCGC) pharmaceutical collection (11), DrugBank (12), the IDAAPM database (13), the phase 4 drugs subset from the ChEMBL 21 release (1) and the e-Drug3D database (14).”
MethodInfluentialThe ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492 · cited 5×
“Mechanism of action annotations in DrugCentral are aggregated from several expert curated resources: ChEMBL database (1), Guide to Pharmacology (2), KEGG Drug (3), as well as manual curations extracted from drug labels and literature.”
BackgroundMethodInfluentialThe SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451 · cited 3×
“Drug adverse events from FDA AERS database (https://open.fda.gov/) and SIDER (21) will be used to enhance the drug safety profile of existing drug reports.”
BackgroundSouthan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035 · cited 3×
“Quantitative bioactivity data are aggregated from multiple sources including: ChEMBLDb (1) (58.73% of the records); DrugMatrix (23) (15.95%); WOMBAT-PK (24) (13.9%); Guide to Pharmacology (2) (5.29%); PDSP (25) (3.41%); scientific literature (2.35%); and drug labels (0.36%), respectively.”
BackgroundMethodInfluentialCalculating log Poct from structures
Leo, A. J. (1993) · Chemical Reviews · doi:10.1021/cr00020a001 · Cited by 695
Dalby, A., Nourse, J. G., Hounshell, W. D., Gushurst, A. K. I., Grier, D. L., Leland, B. A., & Laufer, J. (1992) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00007a012 · Cited by 642 · cited 1×
“A multistep manual curation and validation process was employed to collect, record and store correct chemical information for API molecular structures in the MDL (‘Molecular Design Limited’) MOL format (8).”
Method
Cited by
Items 101–200 of 336
DrugMechDB: A Curated Database of Drug Mechanisms
Gonzalez-Cavazos, A. C., Tańska, A., Mayers, M., Carvalho‐Silva, D., Brindha, S., Rewers, P. A., Sankarlal, U., Jagannathan, L., & Su, A. I. (2023) · Scientific Data · doi:10.1038/s41597-023-02534-z · Cited by 37
Targeting SARS-CoV-2 with AI- and HPC-enabled Lead Generation: A First Data ReleasePreprint
Babuji, Y., Blaiszik, B. J., Brettin, T., Chard, K., Chard, R., Clyde, A., Foster, I. T., Hong, Z., Jha, S., Li, Z., et al. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2006.02431 · Cited by 28
“The collected datasets include some specifically collected for drug design (e.g., Enamine), known drug databases (e.g., Drugbank [7, 8], DrugCentral [9, 10], CureFFI [11]), antiviral collections (e.g., CAS COVID-19 Antiviral Candidate Compounds [12], and the Lit COVID-19 dataset[13]), others that provide known decoys…”
BackgroundMGATRx: Discovering Drug Repositioning Candidates Using Multi-View Graph Attention
Yella, J., & Jegga, A. G. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3082466 · Cited by 26
“Our drug-disease associations consists of 8984 indication pairs (4008 drugs and 2958 diseases) compiled from KEGG [17], FDA [22], DrugCentral [23], and RepoDB [24].”
BackgroundCardioGenAI: a machine learning-based framework for re-engineering drugs for reduced hERG liability
Kyro, G. W., Martin, M. T., Watt, E. D., & Batista, V. S. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-00976-8 · Cited by 28
“5 database to identify any compounds approved by either the FDA, the European Medicines Agency (EMA), or the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) [130, 131].”
Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach
Kumar, N., Sarma, H., & Sastry, G. N. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1905558 · Cited by 24
“, 2006) and DrugCentral (3981 drugs) (Ursu et al., 2017) databases (till Jan 2019).”
Repurposed Molecules: A New Hope in Tackling Neglected Infectious Diseases
Fernandez‐Prada, C., Douanne, N., Minguez-Menendez, A., Pena, J., Tunes, L. G., Pires, D. E. V., & do Monte‐Neto, R. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00005-5 · Cited by 27
Griesenauer, R. H., Schillebeeckx, C., & Kinch, M. S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.010 · Cited by 23
Park, S., & Yi, G. (2022) · Cancers · doi:10.3390/cancers14040881 · Cited by 24
Drug Repositioning Using Computer-aided Drug Design (CADD)
Rawat, S., Subramaniam, K., Subramanian, S. K., Saravanan, S., Dhanabalan, S., Chidambaram, S. K. M., Stalin, B., Roy, A., Nagaprasad, N., Aruna, M., et al. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230821103601 · Cited by 26
A Free Web-Based Protocol to Assist Structure-Based Virtual Screening Experiments
Lagarde, N., Goldwaser, E., Pencheva, T., Jereva, D., Pajeva, I. K., Rey, J., Tufféry, P., Villoutreix, B. O., & Miteva, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184648 · Cited by 23
Xuan, P., Zhang, Y., Cui, H., Zhang, T., Guo, M., & Nakaguchi, T. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab119 · Cited by 26
Abdelwahab, A. A., Elattar, M., & Fawzi, S. A. (2025) · BioMedical Engineering OnLine · doi:10.1186/s12938-025-01412-6 · Cited by 22
“For ADE and toxicity prediction , the FDA Adverse Event Reporting System (FAERS) [60] and DrugCentral [61] offer real-world, post-marketing surveillance data.”
Artificial intelligence streamlines scientific discovery of drug–target interactions
Yang, Y., & Cheng, F. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17427 · Cited by 26
Network Medicine: A Potential Approach for Virtual Drug Screening
Ma, M., Huang, M. J., He, Y., Fang, J., Li, J., Li, X., Liu, M., Zhou, M., Cui, G., & Fan, Q. (2024) · Pharmaceuticals · doi:10.3390/ph17070899 · Cited by 22
Christofidi, M., Tzortzini, E., Mavromoustakos, T., & Kolocouris, A. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00145 · Cited by 21
Evaluating the consistency of large-scale pharmacogenomic studies
Rahman, R., Dhruba, S. R., Matlock, K., Niz, C. D., Ghosh, S., & Pal, R. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby046 · Cited by 23
“DrugCentral [44] v9:4 An online drug compendium where chemical entities, pharmaceutical prod-”
BackgroundFeng, Z., Tang, Y.-C., Sheng, X., Wang, S.-H., Wang, Y., Liu, Z.-C., Liu, J., Geng, B., & Xia, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e12799 · Cited by 19
“DrugCentral [23], a pharmaceutical information resource website, developed by combining information related to active pharmaceutical ingredients (APIs), bioactivity profiles, regulatory information, drug mechanism of action (MoA), pharmaceutical products, pharmacological action, and indications.”
BackgroundKaratzas, E., Minadakis, G., Kolios, G. C., Delis, A., & Spyrou, G. M. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.05.010 · Cited by 20
“The gene targets of the input drugs are found in the parsed DrugBank, DrugCentral [16] and DGIdb [17] databases.”
BackgroundA comprehensive integrated drug similarity resource for in-silico drug repositioning and beyond
Azad, A., Dinarvand, M., Nematollahi, A., Swift, J., Lutze-Mann, L. H., & Vafaee, F. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa126 · Cited by 22
“failures which contains 6,677 approved drug-indication pairs and 4,123 failed drug-indication pairs extracted from DrugCentral [56] and ClinicalTrials.”
BackgroundInfluentialDrew, E. D., & Janes, R. W. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00294-x · Cited by 19
Avram, S., Curpan, R., Halip, L., Bora, A., & Oprea, T. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00826 · Cited by 18
Self-citationA community effort in SARS‐CoV‐2 drug discovery
Schimunek, J., Seidl, P., Elez, K., Hempel, T., Le, T., Noé, F., Olsson, S., Raich, L., Winter, R., Gökcan, H., et al. (2023) · Molecular Informatics · doi:10.1002/minf.202300262 · Cited by 18
“For example, Lyu et al. [110] observe that billion-scale libraries are dramatically diminished for bio-like molecules relative to more focused libraries, yet still contain many experimentally-confirmed actives, as well as thousands of high-ranking molecules in docking assays.”
Drug Repurposing: Insights into Current Advances and Future Applications
Bhatia, T., & Sharma, S. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673266470231023110841 · Cited by 19
Han, S., Lee, J. E., Kang, S., So, M., Jin, H. K., Lee, J. H., Baek, S., Jun, H., Kim, T. Y., & Lee, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae035 · Cited by 19
Design and application of a knowledge network for automatic prioritization of drug mechanisms
Mayers, M., Tu, R., Steinecke, D., Li, T. S., Queralt-Rosiñach, N., & Su, A. I. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac205 · Cited by 20
The human endogenous metabolome as a pharmacology baseline for drug discovery
Bofill, A., Jalencas, X., Oprea, T. I., & Mestres, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.007 · Cited by 17
“Primary pharmacology of drugs and endogenous ligands In vitro binding affinities for drug–target interactions linked to the mechanism of action of the drug were retrieved from the DrugCentral repository [7].”
BackgroundMethodSelf-citationPeng, J. J., Xu, D. S., Lee, R. C., Xu, S., Zhou, Y., & Wang, K. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-01848-z · Cited by 20
“Beyond literature, biomedical researchers also have access to annotated relationships from various biomedical knowledgebases and ontologies, such as protein– protein interactions from STRING [15] and drug-target relationships from DrugCentral [16], to create more comprehensive KGs [17].”
BackgroundPredicting anticancer hyperfoods with graph convolutional networks
Gonzalez, G., Gong, S., Laponogov, I., Bronstein, M. M., & Veselkov, K. (2021) · Human Genomics · doi:10.1186/s40246-021-00333-4 · Cited by 19
John, L., Mahanta, H. J., Soujanya, Y., & Sastry, G. N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106494 · Cited by 17
Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response
Piñero, J., González-Pérez, A., Güney, E., Aguirre‐Plans, J., Sanz, F., Oliva, B., & Furlong, L. I. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00412 · Cited by 17
“, 2018), DrugCentral, data downloaded on September, 2017 (Ursu et al., 2017), DGIdb, version 3.”
Exploiting Cysteine Residues of SLC Membrane Transporters as Targets for Drugs
Scalise, M., Console, L., Galluccio, M., Pochini, L., Tonazzi, A., Giangregorio, N., & Indiveri, C. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219856601 · Cited by 16
Exploring DrugCentral: from molecular structures to clinical effects
Halip, L., Avram, S. I., Curpan, R. F., Borota, A., Bora, A., Bologa, C., & Oprea, T. I. (2023) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-023-00529-x · Cited by 15
Self-citationGualdi, F., Oliva, B., & Piñero, J. (2024) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqae049 · Cited by 17
“…treatments for diseases including different sources: • The drug repurposing database ( 36 ) is a database of gold-standard drug-disease pairs extracted from Drug-Central ( 37 ) and ClinicalTrials.gov • The drug repurposing hub ( 38 ) is a collection of drug-disease including 4707 compounds.”
BackgroundKnowledge Graph Convolutional Network with Heuristic Search for Drug Repositioning
Du, X., Sun, X., & Li, M. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00737 · Cited by 15
A resource to empirically establish drug exposure records directly from untargeted metabolomics data
Zhao, H. N., Kvitne, K. E., Brungs, C., Mohan, S., Charron‐Lamoureux, V., Bittremieux, W., Tang, R., Schmid, R., Lamichhane, S., Xing, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65993-5 · Cited by 16
Xuan, P., Hu, K., Cui, H., Zhang, T., & Nakaguchi, T. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3121798 · Cited by 17
The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity
Reznikov, L. R., Meyerholz, D. K., Alaiwa, M. H. A., Kuan, S., Liao, Y.-S. J., Bormann, N. L., Bair, T., Price, M. P., Stoltz, D. A., & Welsh, M. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00557.2017 · Cited by 15
“Compound classifications were assigned using DrugCentral (95), ChEMBL (56), and PubChem (75).”
MethodIntegrative network analysis interweaves the missing links in cardiomyopathy diseasome
Chauhan, P. K., & Sowdhamini, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-24246-x · Cited by 14
Cancer pharmacoinformatics: Databases and analytical tools
Kamble, P., Nagar, P. R., Bhakhar, K. A., Garg, P., Sobhia, M. E., Naidu, S., & Bharatam, P. V. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01445-5 · Cited by 14
“In addition to the above-mentioned specific data sources, many general-purpose databases such as PDB (Sussman et al. 1998), BindingDB (Chen et al. 2001), PubChem (Kim et al. 2016a, b, c), Uni-Prot (Bairoch et al. 2005), ZINC (Irwin and Shoichet 2005), DrugBank (Wishart et al. 2006), TDR (Tropical Disease Research) tar…”
Applying polypharmacology approach for drug repurposing for SARS-CoV2
Jamir, E., Sarma, H., Priyadarsinee, L., Nagamani, S., Kiewhuo, K., Gaur, A. S., Rawal, R. K., Murugan, N. A., Subramanian, V., & Sastry, G. N. (2022) · Journal of Chemical Sciences · doi:10.1007/s12039-022-02046-0 · Cited by 14
In Silico Databases and Tools for Drug Repurposing
Serçinoğlu, O., & Özbek, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00024-9 · Cited by 16
Kannan, S., O’Connor, G. M., & Bakker, E. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115478 · Cited by 13
Expanding potential targets of herbal chemicals by node2vec based on herb–drug interactions
Zhang, D., Cui, W.-Q., Hou, L., Yang, J., Lyu, L., Wang, Z.-Y., Linghu, K., He, W., Yu, H., & Yuanjia, H. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00763-3 · Cited by 13
Self-citationPolypharmacology guided drug repositioning approach for SARS-CoV2
Jamir, E., Sarma, H., Priyadarsinee, L., Kiewhuo, K., Nagamani, S., & Sastry, G. N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289890 · Cited by 13
“The therapeutic indication of all the drug molecules was identified through DrugBank [44] and DrugCentral [45] databases which were then analysed to identify drugs with a category of therapeutic indications that may be repurposed against 24 SARS-CoV2 targets.”
BackgroundMethodInfluentialOverview of the Knowledge Management Center for Illuminating the Druggable Genome
Oprea, T. I., Bologa, C., Holmes, J., Mathias, S. L., Metzger, V. T., Waller, A., Yang, J. J., Leach, A. R., Jensen, L. J., Kelleher, K. J., et al. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103882 · Cited by 13
Self-citationProteochemometric Modeling for Drug Repositioning
Schaduangrat, N., Anuwongcharoen, N., Phanus‐umporn, C., Sriwanichpoom, N., Wikberg, J. E. S., & Nantasenamat, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00010-9 · Cited by 13
Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond
Precilla, S. D., Kuduvalli, S. S., & Anitha, T. S. (2020) · Cell Biology International · doi:10.1002/cbin.11484 · Cited by 14
Getting Started with the IDG KMC Datasets and Tools
Kropiwnicki, E., Binder, J., Yang, J. J., Holmes, J., Lachmann, A., Clarke, D. J. B., Sheils, T. K., Kelleher, K. J., Metzger, V. T., Bologa, C., et al. (2022) · Current Protocols · doi:10.1002/cpz1.355 · Cited by 13
Self-citationDiscovery of new drug indications for COVID-19: A drug repurposing approach
Kumari, P., Pradhan, B., Koromina, M., Patrinos, G. P., & Steen, K. V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267095 · Cited by 14
“PubChem, Drugbank [6], and Drugcentral [27] have been used to search pharmacological properties of filtered candidate repurposed drug compounds.”
Inferring Drug-Target Interactions Based on Random Walk and Convolutional Neural Network
Xu, X., Xuan, P., Zhang, T., Chen, B., & Sheng, N. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3066813 · Cited by 13
Some Aspects and Convergence of Human and Veterinary Drug Repositioning
Mag, P., Nemes-Terényi, M., Jerzsele, Á., & Mátyus, P. (2024) · Molecules · doi:10.3390/molecules29184475 · Cited by 13
“The Drug Central database, presenting and commenting on human vs. veterinary datasets, also confirms this [144,145].”
BackgroundBlankart, K. E., & Lichtenberg, F. R. (2025) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2025.2472221 · Cited by 12
“Data on drug indications and contraindications were constructed from the DrugCentral database (Avram et al., 2021, 2023; Ursu et al., 2017, 2019 (2024), updated drug indication and contraindication data are covered under a revised license agreement that requires subscription licenses.”
Halu, A., Wang, J., Iwata, H., Mojcher, A., Abib, A. L., Singh, S. A., Aikawa, M., & Sharma, A. (2018) · eLife · doi:10.7554/elife.37059 · Cited by 12
“For the external validation of drug targets, we downloaded drug-target interactions and drug indications from the DrugCentral database (Ursu et al., 2017) (http://drugcentral.”
MethodHow to Prepare a Compound Collection Prior to Virtual Screening
Bologa, C., Ursu, O., & Oprea, T. I. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9089-4_7 · Cited by 13
Self-citationIdentification of Novel Analgesics Through a Drug Repurposing Strategy
Gazerani, P. (2019) · Pain Management · doi:10.2217/pmt-2018-0091 · Cited by 12
CDEK: Clinical Drug Experience Knowledgebase
Griesenauer, R. H., Schillebeeckx, C., & Kinch, M. S. (2019) · Database · doi:10.1093/database/baz087 · Cited by 12
GenCoNet – A Graph Database for the Analysis of Comorbidities by Gene Networks
Shoshi, A., Hofestädt, R., Zolotareva, O. I., Friedrichs, M., Maier, A., Иванисенко, В. А., Dosenko, V., & Bragina, E. Y. (2018) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2018-0049 · Cited by 13
Are drug prices subject to creative destruction? Evidence from the US, 1997–2017
Lichtenberg, F. R. (2021) · Health Economics · doi:10.1002/hec.4283 · Cited by 11
Dyport: dynamic importance-based biomedical hypothesis generation benchmarking technique
Tyagin, I., & Safro, I. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05812-8 · Cited by 14
“DrugCentral [44] is an online drug information resource aggregating information about active ingredients, indications, pharmacologic action and other related data with respect to FDA, EMA and PMDA-approved drugs.”
BackgroundComplex network theory for the identification and assessment of candidate protein targets
McGarry, K., & McDonald, S. (2018) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2018.04.015 · Cited by 11
Advances in Predicting Drug Functions: A Decade-Long Survey in Drug Discovery Research
Das, P., & Mazumder, D. H. (2023) · IEEE Transactions on Molecular Biological and Multi-Scale Communications · doi:10.1109/tmbmc.2023.3345145 · Cited by 10
Wang, Y., Lv, J., Xia, Y., Xu, J., Meng, Y., Cui, F., Wei, L., Zou, Q., & Zhang, Z. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108843 · Cited by 10
Investigation of Possible Herb-Drug Interactions for the Treatment of Cardiovascular Diseases
Zuo, H., Yang, F. Q., & Yuanjia, H. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1692211 · Cited by 10
Xuan, P., Zhang, X., Zhang, Y., Hu, K., Nakaguchi, T., & Zhang, T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac120 · Cited by 10
Predicting Target and Chemical Druggability
Oprea, T. I., & Hasselgren, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12342-x · Cited by 12
Self-citationFormalizing drug indications on the road to therapeutic intent
Nelson, S. J., Oprea, T. I., Ursu, O., Bologa, C. G., Zaveri, A., Holmes, J., Yang, J. J., Mathias, S. L., Mani, S., Tuttle, M. S., et al. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx064 · Cited by 9
“Multiple text-mining tools have been applied(12,21,22) to extract indications, and an open-source compendium mapping molecular entities to indications is available online.(23) While these tools and resources extract disease concepts and map them to existing terminologies, they do not represent the full logic of therap…”
BackgroundSelf-citationLi, Q., Wang, J., Wu, Z., Li, W., Liu, G., & Tang, Y. (2022) · Molecular Informatics · doi:10.1002/minf.202200001 · Cited by 9
Li, C., Jay, N. D., Zhang, S., Fang, X. D., Sharma, S., Catalano, K. A., Sridharan, V., Wang, Z., Zhao, L., Szustakowski, J. D., et al. (2025) · Advanced Genetics · doi:10.1002/ggn2.202500003 · Cited by 11
Xuan, P., Cheng, T., Cui, H., Gu, J., Jin, Q., & Zhang, T. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00136 · Cited by 9
Artificial intelligence in antibiotic discovery: Applications, challenges, and future outlook
Xu, J. B., Li, C., Wang, X., Peleg, A. Y., LI, F., Song, J., & de la Fuente‐Núñez, C. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100445 · Cited by 9
Drug Repositioning Strategies to Explore New Candidates Treating Prostate Cancer
Turanlı, B., & Arğa, K. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00027-4 · Cited by 9
Li, B., Wu, Y.-R., Li, L., Liu, Y., & Yan, Z. (2022) · Molecules · doi:10.3390/molecules27144463 · Cited by 9
Zhou, M., Sun, J., Yu, Z., Wu, Z., Li, W., Liu, G., Ma, L., Wang, R., & Tang, Y. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00018 · Cited by 9
Knowledge-guided generative artificial intelligence for automated taxonomy learning from drug labels
Fang, Y., Ryan, P. B., & Weng, C. (2024) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocae105 · Cited by 11
Nestsiarovich, A., Kerner, B., Mazurie, A., Cannon, D. C., Hurwitz, N. G., Zhu, Y., Nelson, S. J., Oprea, T. I., Unruh, M. L., Crisanti, A. S., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.009 · Cited by 9
Self-citationSviatenko, O., Ríos‐Lombardía, N., Morís, F., González‐Sabín, J., Kollipara, M., Merdivan, S., Guenther, S., Süss, P., & Höhne, M. (2019) · ChemCatChem · doi:10.1002/cctc.201900733 · Cited by 9
Conformal efficiency as a metric for comparative model assessment befitting federated learning
Heyndrickx, W., Arany, Á., Simm, J., Pentina, A., Sturm, N., Humbeck, L., Mervin, L., Zalewski, A., Oldenhof, M., Schmidtke, P., et al. (2023) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2023.100070 · Cited by 14
Computational drug repurposing for viral infectious diseases: a case study on monkeypox
Saha, S., Chatterjee, P., Nasipuri, M., Basu, S., & Chakraborti, T. (2024) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad058 · Cited by 9
Knowledge Mapping of Drug Repositioning’s Theme and Development
Lang, X., Liu, J., Zhang, G., Feng, X., & Dan, W. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s405906 · Cited by 9
“This saves time and resources that would have been required for experimental validation.(90,91) While drug repositioning has numerous advantages, there are also some shortcomings.”
BackgroundPatterson, J., & Tatonetti, N. P. (2024) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocae155 · Cited by 8
Nies, A. T., König, J., Leuthold, P., Damme, K., Winter, S., Haag, M., Masuda, S., Kruck, S., Daniel, H., Spanier, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106941 · Cited by 8
Comprehensive Benchmark Study of Diffusion-Based 3D Molecular Generation Models
Qin, Y., Wei, X.-X., Xu, M., Wu, J., Tang, M., Ran, T., & Chen, H. (2025) · ACS Omega · doi:10.1021/acsomega.5c05077 · Cited by 8
Koniuszewski, F., Vogel, F. D., Dajic, I., Seidel, T., Kunze, M., Willeit, M., & Ernst, M. C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1188101 · Cited by 8
Wang, M., He, L., & Pan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-90211-z · Cited by 7
“Subsequently, 160 TA-related targets were predicted from BATMAN-TCM, DrugCentral, HERB, HIT and Pharmmapper.”
González‐Avendaño, M., Zúñiga-Almonacid, S., Silva, I., Lavanderos, B. J., Robinson, F., Rosales‐Rojas, R., Durán-Verdugo, F., González, W., Cáceres, M., Cerda, O., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.701477 · Cited by 8
“…(Schwede et al., 2003), expression pro fi les from The Human Protein Atlas (Thul and Lindskog, 2018), associated pathologies from DisGeNET (Piñero et al., 2020), as well as drugs modulating the protein function from the DrugCentral (Ursu et al., 2017) and DrugBank (Wishart et al., 2008) databases.”
BackgroundMethodInfluentialApplication of Machine Learning Techniques in Drug-target Interactions Prediction
Zhang, S., Wang, J., Lin, Z., & Liang, Y. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201125105730 · Cited by 7
Approaches for network based drug discovery
Jayachandran, P., Ilango, S., Paital, B., Bhanja, S., & Nirmaladevi, R. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s551 · Cited by 8
“Some databases like DrugBank [107], DrugCentral [112], and KEGG DRUG [123] can be used to obtain the Anatomical Therapeutic Chemical classification (ATC) codes of drugs.”
MethodShingjergji, K., Çelebi, R., Scholtes, J., & Dumontier, M. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103902 · Cited by 7
Ilter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · eLife · doi:10.7554/elife.79747 · Cited by 7
Systems biology approaches to identify driver genes and drug combinations for treating COVID-19
Ebrahimi, A., & Roshani, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-52484-8 · Cited by 7
“In order to identify potential drug combinations against COVID-19, existing drugs that affect each of the identified hub and driver genes based on DrugCentral 47 and KEGG pathways were presented as potential drug targets.”
BackgroundNon-Negative Matrix Factorization for Drug Repositioning: Experiments with the repoDB Dataset.
Bakal, G., Halil Kilicoglu, B., & Kavuluru, R. (2019) · PubMed · Cited by 7
Overcoming Sparseness of Biomedical Networks to Identify Drug Repositioning Candidates
Poleksić, A. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3059807 · Cited by 8
Ravanmehr, V., Blau, H., Cappelletti, L., Fontana, T., Carmody, L., Coleman, B., George, J., Reese, J., Joachimiak, M. P., Bocci, G., et al. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab113 · Cited by 7
“The online drug compendium DrugCentral (16) records experimental activities for approved drugs across all major protein target families (including kinases).”
BackgroundInfluentialSelf-citationKumar, A., Sharanya, C. S., Jayanandan, A., & Sadasivan, C. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12090408.v1 · Cited by 7
Efficient generation of open multi-stage fragmentation mass spectral librariesPreprint
Brungs, C., Schmid, R., Heuckeroth, S., Mazumdar, A., Drexler, M., Šácha, P., Dorrestein, P. C., Petras, D., Nothias-Scaglia, L.-F., Nencka, R., et al. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-l1tqh · Cited by 7
An Evidence-Grounded Research Assistant for Functional Genomics and Drug Target AssessmentPreprint
Sokolova, K., Kosenkov, D., Nallamotu, K., Vedula, S., Sokolov, D., Sapiro, G., & Troyanskaya, O. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.30.697073 · Cited by 9
Bhasuran, B., & Natarajan, J. (2023) · Knowledge and Information Systems · doi:10.1007/s10115-023-01862-1 · Cited by 8
“For the recognition of the remaining medical terms, we used a variety of lexical treasures such as UMLS [49], MeSH [50], HGNC [51], DrugBank [52], and Drug Central [53].”
Kelch, M. A., Vera-Guapi, A., Beder, T., Oswald, M., Hiemisch, A., Beil, N., Wajda, P., Ciesek, S., Erfle, H., Toptan, T., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1193320 · Cited by 7
“Drug selection Aiming for repurposing known drugs including clinically approved drugs for the identified targets, a manually assembled data repository of drugs was set up based on seven public drug databases: Drugbank, ChEMBL, TTD, PharmGKB, BindingDB, IUPHAR/BPS and DrugCentral (49–53, 68, 69).”
BackgroundDongyue, G. A. O., & Zhu, F. (2025) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2025.103196 · Cited by 6
Zhang, H., Liang, S., Xu, T., Li, W., Huang, D., Dong, Y., Li, G., Miller, J. P., Goedegebuure, S. P., Sardiello, M., et al. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag355 · Cited by 6
Metadata
- Authors
- Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I.
- Affiliations
- University of New Mexico (US)
- Corresponding author
- Oprea, Tudor I.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-26
- Volume
- 45
- Issue
- D1
- Pages
- D932-D939
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5210665
- OpenAlex
- W2539985226
- Cited by
- 323
- References
- 29
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 34 · 2023: 39 · 2022: 26 · 2021: 31 · 2020: 45 · 2019: 40 · 2018: 27 · 2017: 17 · 2016: 2
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNM’s Digital Repository (University of New Mexico) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Bioinformatics Institute
- National Institutes of Health
- U.S. Food and Drug Administration
- National Cancer Institute (U54CA189205, P30CA118100)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pharmacopoeia, active pharmaceutical ingredients, FDA-approved drugs, drug labels, drug-target interactions, pharmacological activity, drug indications, drug formulation, text mining, drug adverse events
- MeSH terms
- Drug Compounding, Drug Interactions, Drug Labeling, Pharmaceutical Preparations, Humans, United States, United States Food and Drug Administration, Drug Approval, Search Engine, Databases, Pharmaceutical, Drug-Related Side Effects and Adverse Reactions, Web Browser
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.